PCVX Insider Trading

Insider Ownership Percentage: 3.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $29,335,318.37

Vaxcyte Insider Trading History Chart

This chart shows the insider buying and selling history at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

Vaxcyte Share Price & Price History

Current Price: $30.65
Price Change: Price Increase of +1.53 (5.25%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for PCVX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$30.65Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Vaxcyte (NASDAQ:PCVX)

96.78% of Vaxcyte stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PCVX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$11Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M$0$200MTotal InflowsTotal Outflows
Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More on Vaxcyte

Today's Range

Now: $30.65
Low: $28.75
High: $30.68

50 Day Range

MA: $61.81
Low: $28.04
High: $85.42

52 Week Range

Now: $30.65
Low: $27.66
High: $121.06

Volume

1,724,222 shs

Average Volume

1,218,023 shs

Market Capitalization

$3.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Who are the company insiders with the largest holdings of Vaxcyte?

Vaxcyte's top insider shareholders include:
  1. Grant Pickering (CEO)
  2. Jim Wassil (COO)
  3. Andrew Guggenhime (CFO)
  4. Mikhail Eydelman (SVP)
  5. Elvia Cowan (SVP)
  6. Teri Loxam (Director)
  7. Halley E Gilbert (Director)
  8. Heath Lukatch (Director)
Learn More about top insider investors at Vaxcyte.

Who are the major institutional investors of Vaxcyte?

Vaxcyte's top institutional investors include:
  1. Assenagon Asset Management S.A. — 0.25%
  2. Rhumbline Advisers — 0.14%
  3. Harbor Capital Advisors Inc. — 0.06%
  4. Handelsbanken Fonder AB — 0.03%
  5. SG Americas Securities LLC — 0.01%
  6. GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of Vaxcyte stock.

Which major investors are buying Vaxcyte stock?

In the last quarter, PCVX stock was bought by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. GAMMA Investing LLC
  3. Rhumbline Advisers
  4. SG Americas Securities LLC
  5. Handelsbanken Fonder AB
  6. Harbor Capital Advisors Inc.
  7. Parallel Advisors LLC